Related references
Note: Only part of the references are listed.Autologous tumor-derived heat-shock protein peptide complex-96 (HSPPC-96) in patients with metastatic melanoma
Omar Eton et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2010)
Heat Shock Protein-27, -60 and -90 expression in gastric cancer: association with clinicopathological variables and patient survival
Constantinos Giaginis et al.
BMC GASTROENTEROLOGY (2009)
Tumor escape mechanism governed by myeloid-derived suppressor cells
Srinivas Nagaraj et al.
CANCER RESEARCH (2008)
Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: The C-100-21 study group
Alessandro Testori et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
An adjuvant autologous therapeutic vaccine (HSPPC-96 vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentrel, open-label, randomised phase III trial
Christopher Wood et al.
LANCET (2008)
Altered macrophage differentiation and immune dysfunction in tumor development
Antonio Sica et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Experience with heat shock protein-peptide complex 96 vaccine therapy in patients with indolent non-hodgkin lymphoma
Yasuhiro Oki et al.
CANCER (2007)
Defining the ability of cyclophosphamide preconditioning to enhance the antigen-specific CD8(+) T-cell response to reptide vaccination: Creation of a beneficial host microenvironment involving type IIFNs and myeloid cells
Mohamed L. Salem et al.
JOURNAL OF IMMUNOTHERAPY (2007)
Combined chemoimmunotherapy of solid tumours: Improving vaccines?
Anna K. Nowak et al.
ADVANCED DRUG DELIVERY REVIEWS (2006)
A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-α in metastatic melanoma patients
L Pilla et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2006)
Heat shock protein 70 surface-positive tumor exosomes stimulate migratory and cytolytic activity of natural killer cells
R Gastpar et al.
CANCER RESEARCH (2005)
Natural killer and NK-Like T-Cell activation in colorectal carcinoma patients treated with autologous tumor-derived heat shock protein 96
L Pilla et al.
CANCER RESEARCH (2005)
A single intratumoral injection of a fiber-mutant adenoviral vector encoding interleukin 12 induces remarkable anti-tumor and anti-metastatic activity in mice with Meth-A fibrosarcoma
JQ Gao et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2005)
A phase II trial of interleukin-12 in patients with advanced cervical cancer: clinical and immunologic correlates Eastern Cooperative Oncology Group study E1E96
S Wadler et al.
GYNECOLOGIC ONCOLOGY (2004)
Prevention of angiogenesis by naked DNA IL-12 gene transfer: angioprevention by immunogene therapy
M Morini et al.
GENE THERAPY (2004)
Phase II clinical trial of interleukin-12 in patients with relapsed and refractory non-Hodgkin's lymphoma and Hodgkin's disease
A Younes et al.
CLINICAL CANCER RESEARCH (2004)
Development of cancer vaccines using autologous and recombinant high molecular weight stress proteins
XY Wang et al.
METHODS (2004)
Roles of heat-shock proteins in innate and adaptive immunity
P Srivastava
NATURE REVIEWS IMMUNOLOGY (2002)
Eukaryotic heat shock proteins as molecular links in innate and adaptive immune responses:: Hsp60-mediated activation of cytotoxic T cells
SH Moré et al.
INTERNATIONAL IMMUNOLOGY (2001)
Tumor-derived multiple chaperone enrichment by free-solution isoelectric focusing yields potent antitumor vaccines
M Graner et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2000)
Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guerin (BCG) hsp65 and HPV16 E7
NR Chu et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2000)
Share Paper
